Elucidating the DNA Damage Pathway

For this article, Jennifer Fisher Wilson interviewed Thanos Halazonetis, molecular biologist at the Wistar Institute in Philadelphia; Tak Mak, departments of medical biophysics and immunology at University of Toronto; and Carol Prives, department of biological sciences at Columbia University in New York City. Data from the Web of Science (ISI, Philadelphia) show that Hot Papers are cited 50 to 100 times more often than the average paper of the same type and age. N.H. Chehab et al., "Chk2/hCds1 f

Written byJennifer Fisher Wilson
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

During the 1990s, scientists identified the events downstream of p53 that lead to arrest or apoptosis. Little was known, however, about upstream signaling events that follow DNA damage leading to p53's activation and stabilization. This research led these authors to find the kinase that activates p53. Until this work, "we knew very little about the upstream p53 regulators, only that ATM [Ataxia telangiectasia-mutated] was involved," says Thanos Halazonetis, a molecular biologist at the Wistar Institute in Philadelphia and lead author of one of these papers.

Soon afterward, researcher Robert Abraham at Duke University Medical Center, Durham, NC, showed that another DNA damage sensor, ATR (ATM and Rad-3 related), also functions upstream of p53.4 But the findings suggested that some other kinase, activated by ATM and ATR, must stabilize p53 by phosphorylating on the gene's serine-20 (Ser-20) location.

Meanwhile, biochemist Steve Elledge, Baylor College of Medicine, Houston, cloned a kinase called ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies